Kotak Healthcare Fund-Regular Plan-Growth
Kotak Mahindra Asset Management Co Ltd
₹16.51 (+0.40%)
NAV as of 9 Oct 2026
Minimum Investment: ₹100
Return
22.41% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.40%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹100
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,241
Invested ₹1,000
▲+24.10%1 year
₹1,224
Invested ₹1,000
▲+22.41%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | Nifty Healthcare PR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +22.41% | — | — | — |
| Cumulative returns (%) | +22.41% | — | — | — |
Fund Manager
| Manager | Dhananjay Tikariha |
|---|---|
| Role | Manager |
| Manager Tenure | 2.5 yrs |
About Fund
| Date of Incorporation | 11 Dec 2023 |
|---|---|
| Fund House | Kotak Mahindra Asset Management Co Ltd |
| Custodian | Standard Chartered Bank |
| Registrar / Transfer Agent | Kotak Mahindra Asset Management Co Ltd |
| Address | Standard Chartered Bank,1095 Avenue of the Americas,New York, NY 10036,USA |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 13.96% |
| Divi's Laboratories Ltd | 9.25% |
| J.B. Chemicals & Pharmaceuticals Ltd | 5.45% |
| Torrent Pharmaceuticals Ltd | 4.75% |
| Molbio Diagnostics Ltd | 4.53% |
| Max Healthcare Institute Ltd Ordinary Shares | 4.34% |
| Lupin Ltd | 4.19% |
| Acutaas Chemicals Ltd | 3.91% |
| Cipla Ltd | 3.67% |
| Fortis Healthcare Ltd | 3.46% |
| Park Medi World Ltd | 3.36% |
| Mankind Pharma Ltd | 3.26% |
| Yatharth Hospital and Trauma Care Services Ltd | 3.25% |
| Apollo Hospitals Enterprise Ltd | 3.25% |
| Krishna Institute of Medical Sciences Ltd | 3.12% |
| Sai Life Sciences Ltd | 3.08% |
| Jubilant Pharmova Ltd | 3.05% |
| Gland Pharma Ltd | 2.81% |
Investment Strategy
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved .
Long term capital growth
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.